Docosahexaenoic acid reduces levodopa‐induced dyskinesias in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine monkeys

Abstract

These results suggest that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients.

Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid

“…Then, combined oral administration of L-Dopa and DHA was performed on a daily basis for 1 month. Locomotor activity, as well as parkinsonian and dyskinetic scores of these animals have been previously reported (Samadi et al, 2006). All animals were sacrificed by an overdose of pentobarbital 4 hours after their last L-Dopa dose.…”

“…We previously reported the behavioral data of concomitant administration of DHA with L-Dopa (Samadi et al, 2006). This study showed that DHA significantly reduced LID scores in MPTP-treated monkeys without altering the anti-parkinsonian activity of L-Dopa (Samadi et al, 2006).…”

“…In general, one month was needed to induce a stable parkinsonian syndrome. The cumulative dose to achieve this goal was in average 18.1 ± 3.8 and 13.9 ± 2.5 mg for LDopa and L-Dopa plus DHA groups, respectively (Samadi et al, 2006). The animals were scored several times a week with a disability scale, as previously described (Bélanger et al, 2003).…”

“…The animals were scored several times a week with a disability scale, as previously described (Bélanger et al, 2003). This study was undertaken several months after a stable parkinsonian syndrome had developed (the time after MPTP was 149 ± 63 and 190 ± 42 days for L-Dopa and L-Dopa + DHA groups, respectively) (Samadi et al, 2006). Ten de novo MPTP intoxicated animals were treated with L-Dopa, five received L-Dopa alone, while the others received L-Dopa plus DHA.…”

Docosahexaenoic Acid (DHA), in the Prevention and Treatment of Neurodegenerative Diseases

“…However, as in patients with AD, in the brains of people with PD it is also observed a significant decrease in the levels of n-3 LCPUFA, especially DHA (Johnson et al, 1999). Research in primates allow to observe a significant reduction in the extent of levodopa-induced dyskinesia (a damage model for the PD) in animals supplemented with DHA, which suggests that these effects would be mediated by the activation of retinoid X receptors (RXR) (Samadi et al, 2006). In addition, data from these investigations show a drastic drop in neural DHA levels (Julien et al, 2006;Breckenridge et al, 1973).…”